Renaissance BioScience Secures Landmark Patent for Revolutionary RNA Production and Delivery Technology
Proprietary yeast for producing and delivering RNA bioactive molecules with planned applications in biopesticides, animal health and human medicine
Vancouver, Canada — October 24, 2023 — Renaissance BioScience Corp., a leader in bioengineering for the global agriculture, animal health, human medicine, and food industries, is pleased to announce that it has been awarded the first patent for its innovative yeast-based platform technology for the production and delivery of RNA bioactive molecules. The patent — awarded by the China patent office— joins the company’s extensive IP portfolio of 50 patents issued previously for other innovations and 11 additional applications currently pending in key markets around the world with favourable outcomes anticipated.
Renaissance is utilizing its groundbreaking yeast containing RNA bioactive molecules to initially develop a suite of biological products designed to take a precise, targeted approach to pest control—a significant advance in the large global pest-control market. In addition, this safe and effective platform holds excellent potential in additional multi-billion-dollar market applications in animal health and human medicine. Following years of dedicated research and development, the patent application was filed in May 2019 and the process culminated in the recent approval granted by the Chinese Patent Office. This is significant as China is the world’s largest consumer of pesticides and is also the largest global producer of biopesticides.
Dr. John Husnik, Renaissance’s CSO and Office of the CEO, commented on the patent award: “Securing a patent for our team’s innovative yeast-based RNA platform technology is truly a milestone achievement for Renaissance BioScience. China is an extremely large global market, and the many different large-scale biopesticide, animal health and human medicine applications for this technology represent vast potential markets, not only in China but also many other parts of the world as other patents are awarded. We’re pleased and excited to receive this first patent that recognizes the benefits offered by this dynamic yeast-based RNA technology.”
Yeast-based platform technology addresses key RNA challenges
This new development by Renaissance addresses critical challenges currently facing RNA delivery technologies, including:
- Stability: A yeast’s outer shell is robust, making it an excellent vehicle to protect fragile RNA bioactive molecules in a variety of environments; greatly expanding its applicability.
- Manufacturing: Yeast can be produced at low cost, in high quality and at large scale by general yeast manufacturers, meaning reduced cost of manufacturing of high value RNA bioactive molecules for many different applications.
- Adaptability: Renaissance’s scientists are adept at fine-tuning the platform yeast to address various objectives, including incorporating multiple gene targets and stacking with additional compounds to enhance the carrier’s capabilities in different applications.
- Safety: A food-grade baker’s yeast as the base of the platform, inactivated prior to delivery, is safe for handling and application, easing regulatory concerns regarding its use.
Without RNA human life could not exist. Numerous types of RNA are known, and these are integral to all living things, including the natural foods we eat. For example, Renaissance’s biopesticides utilize RNA interference (RNAi) to precisely target unique proteins essential to the life of the targeted pest. One important feature of RNAi is that it does not create any new functions: it can only switch off or “interfere with” existing functions by turning off a gene’s target activity. Once these specific genes are switched off by the RNAi, the insect dies. And, since these targeted genes are unique to each species, the precision yeast-based RNAi has no negative effect on other insects, animals, humans or plants.
About Renaissance BioScience Corp.
Based in Vancouver, Canada, Renaissance BioScience is a leading bioengineering company whose platform technologies are used to develop innovative, market-ready, functional microorganisms that provide cost-effective solutions to address a broad range of environmental, health and industrial-efficiency challenges. Renaissance BioScience technologies create products for multiple end-use industries, including food and beverage, agriculture, animal/human health and energy. Detailed information about the Renaissance group of companies is available at www.renaissancebioscience.com.
For further information or to arrange interviews, please contact:
Campbell & Company Strategies Inc.
Communications and Public Relations
01 604 888-5267
For commercial or technology development inquiries please contact:
Manager – Business Development & Strategy
For investment inquiries, please contact:
Executive Chairman & Office of the CEO
Caution Regarding Forward-Looking Statements
This press release may include forward-looking statements with respect to the Company based on management’s opinions, estimates and assumptions considering its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Generally, forward-looking statements can be identified using terminology such as “anticipate”, “will”, “expect”, “may”, “continue”, “could”, “estimate”, “forecast”, “plan”, “potential” and similar expressions. The forward-looking statements contained in this press release are made as of the date hereof.
Forward-looking statements contained in this press release may include, but are not limited to: statements with respect to the successful execution of the Company's business and investment strategy (including its business model), the Company’s intellectual property, entrance of the Company’s business into new markets, the use and benefits of its products and services, the Company’s favourable position in the market on a go-forward basis, demographic and market size/trends, forecasts of revenue and financial projections/growth potential, competitive analysis, projected milestones, go-forward management, go-forward capitalization, anticipated governmental and regulatory approvals and other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance, review and approval dates, start-up timelines and schedules and statements related to the continued overall advancement of the Company’s business.
By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. In addition, the forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. There is significant risk that the forward-looking statements will not prove to be accurate, that the Company’s assumptions may not be correct and that actual results may differ materially from such forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements.
Except as required by law, the Company undertakes no obligation to update publicly or to revise any forward-looking statements that are contained or incorporated in this press release. All forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Back to all news